Compare COHU & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | AMPH |
|---|---|---|
| Founded | 1947 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1994 | 2005 |
| Metric | COHU | AMPH |
|---|---|---|
| Price | $27.16 | $18.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $33.25 | $30.29 |
| AVG Volume (30 Days) | ★ 848.8K | 499.1K |
| Earning Date | 05-14-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | $452,956,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $14.38 | $7.34 |
| Revenue Next Year | $19.12 | $4.81 |
| P/E Ratio | ★ N/A | $9.54 |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $12.59 | $18.94 |
| 52 Week High | $34.96 | $31.26 |
| Indicator | COHU | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.73 | 23.97 |
| Support Level | $18.61 | N/A |
| Resistance Level | $31.18 | $28.56 |
| Average True Range (ATR) | 1.25 | 1.19 |
| MACD | -0.56 | -0.89 |
| Stochastic Oscillator | 4.79 | 2.56 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.